Bayer | Oncology

At #SIOP2025, long-term data on pediatric patients with TRK fusion primary and non-primary CNS tumors were presented, highlighting durable responses, extended survival, and a favorable safety profile — reinforcing the role of genomic testing to identify patients who may benefit from targeted treatment early. SIOP 2025, SHIFT 01–228 F. Doz and SIOP2025 SHIFT 01–229 T.W. Laetsch https://lnkd.in/g5u984y6 #SIOP2025 #TRKfusion #PediatricOncology #TeamBayer

#ESMO2025 Updates ! From exciting new data in mHSPC and HER2-mutant NSCLC to inspiring patient initiatives such as the Outdoor Against Cancer session on physical activity and the Europa Uomo “Step Out for Prostate Cancer” awareness run, there was a lot happening in Berlin. And if you couldn’t join us on the 17th for the run, there’s still plenty of time to take part in the Europa Uomo virtual run — open until 30 November 2025. 🏃➡️ Click Here to register: https://lnkd.in/g3ZS9zkm Stay tuned for more insights from #ESMO2025.   ESMO 2025 , Abstract LBA92 ESMO 2025, Abstract LBA75 Data published in NEJM: https://www.nejm.org/  https://lnkd.in/gyM6h-w4 #TeamBayer #OncologyInspired #ESMO25 #ProstateCancerAwareness #OutdoorAgainstCancer #EuropaUomo

⏳ Only 1 day left until #ESMO25 We are waiting eagerly to meet you!   At #ESMO25, key sessions and posters will highlight: 🔹 Quality-of-life and safety outcomes across different patient subgroups 🔹 Real-world experiences with advanced hormonal therapies in non-metastatic disease 🔹 Novel multimodal strategies, including the integration of systemic therapy with radiation and chemotherapy 🔹 Patient perspectives on symptom burden and the impact of hormone therapy   These discussions reflect a shared goal: delivering more personalized, evidence-driven care for patients across the prostate cancer journey.   📍 Join us in Berlin to be part of the dialogue shaping the future of prostate cancer management. 📅 Don’t miss the poster sessions on October 18    At the same time, we recognize that awareness is just as important as science.   That’s why we’re proud to support Europa Uomo in the “Step Out for Prostate Cancer” awareness run and walk during #ESMO25 — There are two ways you can take part and help raise funds for prostate cancer awareness:   Join in Berlin, register here https://lnkd.in/dcZYCk5Z happening on October 17, 8 - 10 AM, STADION TSV, Berlin.   Virtual run/walk, register here https://lnkd.in/g3ZS9zkm and take part anytime through Nov 30th.     Together, let’s unite for men’s health—inside the clinic and beyond.   Meet us at Booth 3027   #ESMO25 #OncologyInspired #TeamBayer #ProstateCancer Anita Trippe Peter Said Erik Briers

Physical activity is gaining momentum as a vital part of cancer recovery. Evidence shows that structured exercise can improve treatment tolerance, reduce fatigue, and enhance quality of life for patients with cancer (Herranz-Gómez et al., Arch Phys Med Rehabil 2023; Walker et al., J Surg Oncol 2024). In conversation with Ph.D. Rūdolf Cešeiko from Outdoor Against Cancer, we explore how movement — something so simple yet powerful — is redefining holistic cancer care. OAC will be attending #ESMO2025 — get in touch with them to learn more about their initiatives. And if you’d like to continue the discussion, visit us at Booth 3027 #TeamBayer #OncologyInspired #OutdoorAgainstCancer #ESMO25 #CancerCare Petra Thaller Dr. Sylvi Lucke Dr Kishan Rees Dr. med. Tom Degenhardt

We had an excellent EANM25 Congress in Barcelona ! Thank you to all who joined us and contributed to the rich scientific exchange. Here are some highlights from our participation at #EANM25.   This year’s discussions spotlighted how radiopharmaceuticals are redefining care for patients with mCRPC.   The opening ceremony marked the 40th anniversary of EANM, celebrating four decades of innovation in nuclear medicine 🎉   Sessions featured new data on combination approaches with radiopharmaceuticals in mCRPC.   The congress showcased the growing innovation and expanding relevance of radiopharmaceuticals—not only in prostate cancer but across emerging therapeutic areas.   Explore more in the abstracts: https://lnkd.in/gq75xHCM We look forward to continuing the dialogue at ESMO25 in Berlin! #EANM25 #ESMO25 #Oncology #TeamBayer #ProstateCancer Andreas SutterRaphaël BierlaireDominic RedmondJulio Pozueta PhD

Only 3 days to go until #ESMO25 ! Ready for a knowledge snack for preparation?   💡 Did you know, that up to 40% of patients that progressed from mHSPCto mCRPC did not recieve prior ARPI Treatment?   To learn more about the latest evidence in mCRPC, mark your calendars and visit the following sessions:      ▶️ Outcomes and safety of adding a radiopharmaceutical to hormonal therapy in bone-metastatic prostate cancer. ▶️Dual radiopharmaceutical strategy in advanced prostate cancer.   ▶️Real-world insights on bone health and treatment sequencing in prostate cancer with bone metastases.   For any other questions feel free to come by and visit our booth #3027! #ESMO2025 #OncologyInspired #TeamBayer #ProstateCancer    1. Castro E, et al. Presented at: ISPOR; May 5–8, 2024; Atlanta, Georgia. Abstract HSD35.  2. Raval AD, et al. JCO Oncol Pract. 2025; 21(8):1174-1184

4 days to go until #ESMO25 - Are you ready?   Treatment sequencing and novel combinations continue to play a critical role in addressing unmet needs across GI and liver cancers.   To learn more about the latest evidence, mark your calendars for these upcoming sessions:   Oct 17 Strategies in gastric & gastroesophageal junction cancers Oct 19 Latest insights in colorectal cancer management Oct 19 & 20 Advances in glioblastoma, liver & melanoma care   Curious to dive deeper? Join the discussion with us at Booth #3027 — and explore how research is shaping future directions in cancer care.     #ESMO25 #OncologyInspired #ClinicalResearch #GIcancer #LiverCancer #Melanoma

Only 5days left until #ESMO25 ! Let us share a great reason to join: The Bayer industry satellite symposium Future Now: Emerging Evidence-Based Treatment Strategies in mCRPC   Join us, listen in and learn more about: -The current treatment landscape and its implications in mCRPC - Latest evidence-based treatment considerations -Challenging treatment scenarios from clinical practice that broaden your knowledge   We invite you to discuss with our expert faculty the latest evidence to tailor and improve patient care!   For any further information, visit the ESMO website. https://lnkd.in/dznwdsWE #ESMO2025 #OncologyInspired #TeamBayer #ProstateCancer 

Only 6 days to go until #ESMO25   TRK fusion cancers, though rare, can affect patients across many different tumor types.   At this year’s congress, new insights will focus on: 🔹 Real-world experiences of patients treated for TRK fusion cancers 🔹 Long-term outcomes in primary CNS tumours with TRK fusion 🔹 Efficacy and safety in patients with TRK fusion cancer who have achieved complete or long-term response   These findings highlight how precision oncology can deliver meaningful impact helping to inform future care approaches.   Join the conversation with leading experts, Lorena Valero-Arresse, MD; Jonathan C. Trent, MD PhD; Noah Federman, MD; and David S. Hong, MD at #ESMO25 as science and real-world evidence come together for patients with TRK fusion cancers.   Mark your Calendars :   Posters – 19th Oct Mini-Oral – 20th Oct   #OncologyInspired #TeamBayer #ESMO25 #PrecisionOncology